ERBB2 and breast cancer: Using TCGA breast cancer data (57), we demonstrated that a FOXM1 target gene signature (including FOXM1) was enriched in poor-outcome luminal B, HER2+, and triple-negative breast cancer (TNBC) subtypes, but not in luminal A or normal-like subtypes (Supplemental Figure 10C).